119 related articles for article (PubMed ID: 2108885)
1. Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients.
Mazzei T; Mini E; Rizzo M; Periti P
J Int Med Res; 1990; 18 Suppl 1():42-56. PubMed ID: 2108885
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
[TBL] [Abstract][Full Text] [Related]
3. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group.
Bischoff W
J Int Med Res; 1990; 18 Suppl 1():103-13. PubMed ID: 2108882
[TBL] [Abstract][Full Text] [Related]
4. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
Khan MS; O'Brien A
Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
[TBL] [Abstract][Full Text] [Related]
6. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
Navratil H
J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
[TBL] [Abstract][Full Text] [Related]
7. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial.
Rizzo M; Mazzei T; Mini E; Bartoletti R; Periti P
J Int Med Res; 1990; 18 Suppl 1():114-25. PubMed ID: 2108883
[TBL] [Abstract][Full Text] [Related]
8. Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group.
Akaza H; Aso Y; Koiso K; Fuse H; Isurugi K; Okada K; Usami M; Kotake T; Ohashi T; Ueda T
J Int Med Res; 1990; 18 Suppl 1():90-102. PubMed ID: 2108889
[TBL] [Abstract][Full Text] [Related]
9. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer.
O' Brien A; Hibberd M
J Int Med Res; 1990; 18 Suppl 1():57-68. PubMed ID: 2108886
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of depot leuprorelin.
Periti P; Mazzei T; Mini E
Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance.
Toguchi H
J Int Med Res; 1990; 18 Suppl 1():35-41. PubMed ID: 2138986
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer.
Bourdin S; Karam G; Clemain P; Bouchot O; Peuvrel P; Lacoste J; Auvigne J
J Int Med Res; 1990; 18 Suppl 1():74-8. PubMed ID: 2108888
[TBL] [Abstract][Full Text] [Related]
15. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
Tunn UW; Wiedey K
Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
[TBL] [Abstract][Full Text] [Related]
16. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
Eri LM; Haug E; Tveter KJ
Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
[TBL] [Abstract][Full Text] [Related]
17. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
Fornara P; Jocham D
Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
[TBL] [Abstract][Full Text] [Related]
19. Interim report of a large French multicentre study of efficacy and safety of 3.75 mg leuprorelin depot in metastatic prostatic cancer.
Giraud B
J Int Med Res; 1990; 18 Suppl 1():84-9. PubMed ID: 1691113
[TBL] [Abstract][Full Text] [Related]
20. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
